Welcome to our dedicated page for MIMEDX GROUP SEC filings (Ticker: MDXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MiMedx Group, Inc. filings document the regulatory record for a Florida-incorporated regenerative biomaterials company serving wound care, burn and surgical healthcare markets. Form 8-K reports furnish quarterly and annual operating results, earnings materials, Regulation FD investor presentations and material events tied to business updates.
The company’s proxy materials cover board elections, executive compensation, equity-award valuation, pay-versus-performance data and shareholder voting matters. Recent current reports also document restructuring-related officer changes and temporary compensation reductions for named executive officers, linking governance disclosures to changes in the company’s cost structure.
MIMEDX GROUP, INC. Chief Financial Officer Doug Rice reported an automatic share disposition related to tax obligations, rather than an open-market trade. On vesting of restricted stock units, 12,749 shares of common stock were withheld at $3.95 per share to cover tax liabilities. After this tax-withholding event, Rice directly holds 399,566 shares of MIMEDX common stock, indicating that the filing reflects routine compensation-related administration instead of a discretionary buy or sell decision.
MIMEDX GROUP, INC. Chief Commercial Officer Kimberly Maersk-Moller reported a compensation-related share transaction. On the vesting of restricted stock, 19,820 shares of common stock were withheld by the company at $3.83 per share to satisfy tax obligations.
This tax-withholding disposition is not an open-market sale and does not reflect a discretionary trade. After the withholding, Maersk-Moller holds 309,630 shares of MIMEDX common stock directly, showing she retains a substantial equity position in the company.
MiMedx Group, Inc. reported governance updates and 2026 annual meeting results. The board amended the Amended & Restated Bylaws to allow the chief executive officer to serve on up to three boards of directors of public companies.
At the 2026 Annual Meeting, 125,360,965 common shares, representing approximately 84.2% of eligible votes, were present in person or by proxy. Shareholders re‑elected the nominated directors, approved an advisory resolution on executive compensation, and ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
BIERMAN JAMES L reported acquisition or exercise transactions in this Form 4 filing.
MIMEDX GROUP, INC. director James L. Bierman received an annual restricted stock grant of 50,913 shares of common stock on June 10, 2026 at $3.64 per share. The award to this non-employee director vests upon the earlier of 12 months or the next meeting of shareholders, bringing his direct holdings to 263,684 shares. This is a compensation-related equity award, not an open-market purchase.
PUHY DOROTHY E reported acquisition or exercise transactions in this Form 4 filing.
MiMedx Group director Dorothy E. Puhy received a grant of 50,913 shares of common stock at $3.64 per share as an annual restricted stock award for non-employee directors. This compensation-related grant, exempt under Rule 16b-3, will vest upon the earlier of 12 months or the next shareholder meeting. Following the award, she directly holds 108,510 shares of MiMedx common stock.
MIMEDX GROUP, INC. director Todd Newton received an annual restricted stock award, acquiring 50,913 shares of common stock at a reference price of $3.64 per share as director compensation. The grant is exempt under Rule 16b-3 and will vest upon the earlier of 12 months or the next shareholder meeting. Following this award, Newton directly holds 463,684 shares of MIMEDX common stock.
HAWKINS WILLIAM A reported acquisition or exercise transactions in this Form 4 filing.
MIMEDX GROUP, INC. director William A. Hawkins received an annual restricted stock grant of 50,913 shares of common stock at $3.64 per share. This grant is compensation for his service as a non-employee director and is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next meeting of shareholders. Following this grant, Hawkins directly holds 254,931 shares of MIMEDX common stock.
Olson Tiffany reported acquisition or exercise transactions in this Form 4 filing.
MIMEDX GROUP, INC. director Tiffany Olson received an award of 50,913 shares of common stock at $3.64 per share as a restricted stock grant for non-employee directors. This equity award vests upon the earlier of 12 months or the next meeting of shareholders, and is exempt under Rule 16b-3. Following the grant, she directly holds 108,510 shares of common stock. This is a compensation-related equity grant rather than an open-market purchase.
MiMedx Group, Inc. files its annual report describing operations centered on placental allografts, a growing wound-care and surgical portfolio, and recent expansion into xenografts and distribution agreements. The report states $719 million aggregate market value of non-affiliate common equity and 148,566,586 shares outstanding as of February 19, 2026.
The company highlights regulatory engagement with the FDA (including an RFD and litigation concerning AXIOFILL), Medicare reimbursement changes effective January 1, 2026 (a new flat rate of $127.14 per cm2), expansion into Japan with reimbursement at 35,100 Yen/cm2, ongoing clinical evidence generation (including an EPIEFFECT RCT), and strategic priorities to broaden products and grow surgical adoption. Revenue seasonality, reliance on donor tissue, and competitive/reimbursement risks are emphasized.
MiMedx Group, Inc. is holding its 2026 annual shareholder meeting as a virtual-only webcast on June 10, 2026, at 9:00 a.m. Eastern time. Shareholders of record at 5:00 p.m. Eastern time on April 13, 2026, may vote.
Investors are asked to elect seven directors, approve on an advisory basis the Company’s executive compensation, and ratify Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026. The Board unanimously recommends voting in favor of all proposals.
The proxy also discusses 2025 performance, including 20% net sales growth, a 12% GAAP net income margin, a 25% adjusted EBITDA margin, and $74 million of operating cash flow, reflecting strong profitability and cash generation alongside strategic product launches and reimbursement changes.